Avacta Group Share Forecast, Price & News

GBX 129
-2.40 (-1.83 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume895,596 shs
Average Volume2.90 million shs
Market Capitalization£327.21 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

Avacta Group logo

About Avacta Group

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in three segments: Diagnostics, Therapeutics, and Animal Health. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.68 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Avacta Group (LON:AVCT) Frequently Asked Questions

What stocks does MarketBeat like better than Avacta Group?

Wall Street analysts have given Avacta Group a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avacta Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avacta Group's next earnings date?

Avacta Group is scheduled to release its next quarterly earnings announcement on Monday, September 27th 2021.
View our earnings forecast for Avacta Group

How were Avacta Group's earnings last quarter?

Avacta Group Plc (LON:AVCT) announced its quarterly earnings data on Monday, September, 28th. The biotechnology company reported ($3.74) earnings per share for the quarter.
View Avacta Group's earnings history

How has Avacta Group's stock price been impacted by COVID-19 (Coronavirus)?

Avacta Group's stock was trading at GBX 22.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVCT shares have increased by 467.0% and is now trading at GBX 129.
View which stocks have been most impacted by COVID-19

Who are Avacta Group's key executives?

Avacta Group's management team includes the following people:
  • Dr. Alastair Smith, CEO & Exec. Director
  • Mr. Tony Gardiner, CFO, Company Sec. & Exec. Director (Age 50, Pay $191k)
  • Mr. Michael Vinegrad, Director of Group Communications
  • Ms. Joanne Soundy, Commercial Marketing Mang. of Diagnostics
  • Dr. Matt Johnson, Chief Scientific Officer of Diagnostics
  • Dr. Amrik Basran, Chief Scientific Officer of Therapeutics
  • Dr. Matthew P. Vincent, Sr. VP of Bus. Devel. & Innovation Strategy - Therapeutics
  • Dr. Neil Bell, Chief Devel. Officer of Therapeutics (Age 63)
  • Ms. Mary Bronserud, Operations Director of Diagnostics & Animal Health

Who are some of Avacta Group's key competitors?

What other stocks do shareholders of Avacta Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avacta Group investors own include Legal & General Group (LGEN), SkinBioTherapeutics (SBTX), Augean (AUG), 7digital Group (7DIG), American Airlines Group (AAL), ACI Worldwide (ACIW), Akero Therapeutics (AKRO), (ALT), Advanced Micro Devices (AMD) and Amyris (AMRS).

What is Avacta Group's stock symbol?

Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT."

How do I buy shares of Avacta Group?

Shares of AVCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Avacta Group's stock price today?

One share of AVCT stock can currently be purchased for approximately GBX 129.

How much money does Avacta Group make?

Avacta Group has a market capitalization of £327.21 million and generates £3.64 million in revenue each year.

How many employees does Avacta Group have?

Avacta Group employs 123 workers across the globe.

What is Avacta Group's official website?

The official website for Avacta Group is www.avacta.com.

Where are Avacta Group's headquarters?

Avacta Group is headquartered at Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom.

How can I contact Avacta Group?

Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The biotechnology company can be reached via phone at +44-1904-217070.

This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.